Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:HIMS News 9 January 2026 - 6 February 2026

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
····
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
···
Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next

Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next

Hims & Hers shares fell 2.2% to $31.00 in premarket trading Monday after a 6.4% drop Friday. The decline followed Amazon Pharmacy’s move to offer Novo Nordisk’s Wegovy weight-loss pill nationwide, intensifying competition in the online obesity drug market. Investors are watching Hims’ upcoming earnings for signs of pressure on its GLP-1 business and marketing costs.
12 January 2026
·
Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers Health shares dropped 6.4% to $31.69 Friday, extending a two-day slide to 11% after Amazon Pharmacy entered the Wegovy weight-loss pill market. BofA cut its price target and kept an Underperform rating, citing high 2026 estimates. The stock closed below key moving averages and neared oversold levels. The FDA previously warned the company over marketing claims for compounded weight-loss drugs.
10 January 2026
··
Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers shares dropped 5.3% to $32.06 after Amazon Pharmacy began offering Novo Nordisk’s Wegovy weight-loss pill. Bank of America cut its price target on Hims, citing margin and spending risks for 2026. The stock fell from an intraday high of $34.35. Investors are watching for signs of pricing pressure and updated forecasts ahead of Hims’ next earnings report.
9 January 2026
··

Stock Market Today

T-Mobile stock price slides into the weekend as Feb. 11 earnings update looms

7 February 2026
New York, Feb 7, 2026, 16:46 EST — Market closed. T-Mobile US shares fell 2.2% on Friday to close at $197.39, snapping a three-session rise and lagging telecom peers in a broad market rebound. The stock traded about 5.1 million shares, a bit below its 50-day average, and ended roughly 29% below its 52-week high. (MarketWatch) The drop leaves investors staring at a tight calendar: T-Mobile plans to report fourth-quarter and full-year 2025 results on Feb. 11 and pair the call with a capital markets day update — a briefing where executives lay out targets and priorities. The company said
Go toTop